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ABSTRACT
AIM
To study the diagnostic significance of nerve conduction studies in
early detection of pure neuritic hansen's disease.
INTRODUCTION
Hansen's disease is diagnosed by presence of skin lesions. However,
in case of pure neuritic hansen's the diagnosis is delayed because of
absence of skin lesions.  The delay in diagnosis leads to delay in treatment
which leads to formation of deformities. This study is aim that whether
nerve conduction studies are helpful in subjecting the patient to early nerve
biopsy.
MATERIALS AND METHODS
This  study  is  a  descriptive  study  of  analysing  the  patients  with
clinical suspicion of pure neuritic Hansen's electro physiologically and
later corrlating with the nerve biopsy results.
70 patients attending neurology OPD with clinical suspicion of pure
neuritic hansen's disease were selected.
Patients were evaluated for other diseases which can mimic
Hansen's disease.
Patients were subjected to sural nerve biopsy and then the findings
were correlated with electro physiology.
RESULTS
16 out of 70 patients were diagnosed to have Hansen's disease by
biopsy. The most common mimickers for Hansen's were Diabetic
Neuropathy, HMSN and connective tissue disorders.
Nerve conduction studies including sympathetic skin response were
abnormal in all patients with Hansen's disease. It was also abnormal in
other diseases like Diabetic Neuropathy and connective tissue disorders.
CONCLUSION
All the patients with biopsy proven Hansen's disease showed
abnormal nerve conduction studies.
Since nerve conduction studies were also abnormal in other diseases
it is not specific for Hansen's and based on that alone we cannot subject the
patients for nerve biopsy.
Nerve biopsy clinches the diagnosis.
1INTRODUCTION
Leprosy is a chronic granulomatous infection, principally affecting the skin
and peripheral nerves, caused by the obligate intracellular organism
Mycobacterium leprae. Leprosy is the most common treatable cause of
neuropathy. It is one of the oldest diseases endemic in India. It continues to
be an important health problem worldwide but is most prevalent in India,
Brazil, Democratic Republic of Congo, Tanzania, Nepal, Mozambique,
Madagascar, Angola, and the Central African Republic.1.The clinical range
from tuberculoid to lepromatous leprosy is a result of variation in the cellular
immune response to the mycobacterium. The resulting impairment of nerve
function causes the disabilities associated with leprosy. It is of high social
concern as its complications leads to deformities which leads to social
stigma and decreased quality of life. The diagnosis is often delayed because
of the prolonged incubation period. The compliance of the patients with
respect to treatment is also poor because of the prolonged treatment period.
The diagnosis is further delayed when the disease presents as the pure
neuritic form in which there are no skin lesions. A stage of functional
blockade of conduction of nerve impulse almost always precedes visible
pathological changes in the nerve. The role of electrophysiological
evaluation of nerve function in the diagnosis and assessment of different
neuropathies is well established A significant decline of motor nerve
2conduction velocities has also been reported in clinically normal nerves in
leprosy. This study is aimed at whether electrophysiology can help in the
early detection of nerve involvement in pure neuritic disease which may aid
in the early treatment of the disease decreasing the morbidity. This study
also tries to correlate the clinic electrophysiological findings with that of the
nerve biopsy.
3AIM AND OBJECTIVES
1. To study the diagnostic significance of nerve conduction studies in
early    detection of Pure Neuritic Hansen’s disease
2. To study the correlation between sympathetic skin response and
nerve biopsy.
3. To study the electrophysiological correlation in biopsy proven
Hansen’s disease
4REVIEW OF LITERATURE
INTRODUCTION
The earliest report of Leprosy dates back to 600 bc. In 1864 G. Armour
Hansen reported  his observations on tissue from a Norwegian patient and
became the first to link a bacterium to human disease. This organism, which
later came to be known as Mycobacterium leprae, is one of the important
causes of treatable neuropathy worldwide. The most likely mode of
transmission is through nasal
secretions and skin contact. The disease is thought to be of low infectivity.
In most populations, over 95% of individuals are naturally immune.2.
Leprosy was recognized in the ancient civilizations of China, Egypt and
India.
PATHOGENESIS
M. leprae multiplies very slowly and the incubation period is about five
years. Symptoms can take as long as 20 years to appear. Nerves, which are
generally resistant to bacterial infections are consistently invaded by M.
leprae. Another extraordinary feature is that the critical temperature required
for multiplication of M. leprae. It fails to multiply at core body temperature
of 37 ?C and optimal growth occurs at 27–30 ?C which is responsible for the
5occurrence of leprosy in superficial and cooler areas such as skin, nerves,
testis and upper respiratory tract. Peripheral neuropathy is the main cause of
morbidity in leprosy and responsible for most of the disabilities and
deformities displayed by many leprosy patients 3,4.
The nerve damage affects sensory, motor, and autonomic fibers. These nerve
lesions are characterized by a chronic or subacute inflammatory infiltrate
containing epithelioid cells or M. leprae-glutted macrophages. This infiltrate
will occupy the endoneurium, perineurium and epineurium which leads to
progressive impairment of unmyelinated and myelinated neural fibers
followed by a replacement of the peripheral nerve parenchyma with fibrous
tissue 5,6. Necrotic caseation in tuberculoid granulomas can lead to abscess
formation and complete destruction of the nerves 7.  Pure  neuritic  form  of
neuropathy may present without skin lesions. Pure neuritic form has a varied
incidence among the total number of cases in an endemic leprosy population
comprising 4–10% of patients. Males are significantly more affected than
females 8,9. In this neuropathy, the small nerve fibers conducting pain and
temperature sensations are affected significantly before the large myelinated
fibers that conduct vibration sense, position sense, and motor impulses. This
selective sequential involvement of the nerve fibers impairs the detection of
leprosy neuropathy at the initial stages of the disease by neurophysiological
evaluation since routine nerve conduction studies only record potentials
originating from fibers wider than 7?m in diameter. Histologic preparations
6in these patients usually show changes compatible with borderline or
tuberculoid leprosy 3,10.
Clinical features:
Leprosy mainly affects the skin and nerves and resembles many
dermatologic and neurologic conditions. If left untreated the disease is
progressive and results in permanent damage to the skin, nerves, limbs and
eyes.
Classification:
Leprosy can be classified according to the number of skin lesions present
and the number of bacilli found on slit-skin smear examination.
Paucibacillary disease (indeterminate, tuberculoid tuberculoid (TT) and
borderline tuberculoid (BT) forms) is defined as fewer than six skin lesions
with no bacilli on slit-skin smear testing. Multibacillary disease (borderline
borderline (BB), borderline lepromatous (BL) and lepromatous leprosy (LL)
forms) is characterized by six or more lesions with or without positive skin
smear results. To avoid treatment failure in PB patients with positive skin-
slit smears it is recommended that such cases should be classified as
multibacillary disease 11. Skin manifestations and neurological involvement
depends on the stage of disease and immunological status of the patient.
7Table .1
Clinical features of different stages in leprosy
Type Skin lesions Nerve lesions
Lepromatous
(little/no cellular
immunity,anergic)
Wide and symmetrical
distribution
Nerve damage slow and
progressive
Slight pigmentation or
erythema
Hypoesthesia over extensor
surface of the legs,feet,
forearms and hands
Smooth and shiny surface Late
features-impaired sweating,
hair growth, loss of sensation
Distal weakness-intrinsic
muscles of hands and feet
Dry, scaly appearance
Impairment of sweating
Tuberculoid
(strong cell-mediated
immunity,
<6 lesions
Enlargement of single nerve is
common
lymphocytic infiltration)
Asymmetric distribution Marked nerve damage can
occur
Well circumscribed May result in wrist drop,
clawing of the hand and foot
8drop
Elevated margins Commonly involves the
greater auricular, radial
cutaneous,
ulnar, common peroneal
posterior tibial nerve
Marked hypopigmentation
Lesions typically hairless
anesthetic
Indeterminate
(intermediate immunity
status)
Hypo-pigmented
Nerve involvement irregular
and asymmetrical
Ill-defined Heal on their own
in 75% cases
Early anesthesia
Ignored by patients
Borderline
 (intermediate immunity
status)
Abundant Various degree of
symmetry, definition and
pigmentation
9Lepromatous leprosy (LL):
Lepromatous leprosy is a generalized disease with multisystem involvement,
sparing only the central nervous system. Most strikingly involves the skin,
mucous membranes, nerves and reticuloendothelial systems. Lesions
involving the skin are multiple, bilateral, and symmetrical. Typically these
lesions are hypopigmented (sometimes mildly erythematous), shiny with ill-
defined margins and merges imperceptibly with surrounding skin.
Characteristically it involves eyebrows, nose, and lips, along with flattening
of the bridge of the nose resulting in classical ‘leonine facies’. Nerve
involvement results in progressive bilateral symmetrical cutaneous sensory
loss. The nerve trunks tend to be bilaterally and symmetrically thickened and
tender 12,13
Tuberculoid tuberculoid (TT):
Tuberculoid tuberculoid leprosy is characterized by a well-defined uniformly
circular or oval erythematous/ hypopigmented plaque with maximal
induration of the margins sloping towards the centre and appearing like “a
saucer the right way up”. The surface is bald, dry and scaly, and completely
anaesthesthetic. These lesions usually number from one to three in a patient
and a thickened (sometimes tender) nerve in the vicinity is usually palpable
12,13.
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Indeterminate (I) leprosy
This expression of the disease is a prelude to the determinate forms of the
disease. It is diagnosed when there is a single lesion or only a few macules,
with well or ill-defined margins and variably impaired sensations. The
surface may be smooth or mildly scaly, and a thickened nerve supplying the
lesion(s) may or may not be palpable clinically. Seventy-five percent of the
lesions in indeterminate leprosy heal spontaneously and they are ignored by
many patients.
Borderline lepromatous (BL)
Borderline lepromatous leprosy shares features of BB; however lesions
resembling BT are out-numbered by lepromatous (LL) type of lesions. The
lesions have variable sensory loss, tend to vary in number from countable to
uncountable, and they are bilaterally distributed with a tendency towards
symmetry. Symmetrical involvement of the nerves in the form of thickening
and/or tenderness along with sensory loss not limited to clinically apparent
skin lesions are features that help in the diagnosis 12,13.
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Borderline tuberculoid (BT)
Borderline tuberculoid leprosy is recognized as hypopigmented and/or
erythematous macules or plaques with well-defined irregular margins. The
surface of the lesion(s) is bald, dry, and scaly with variable sensory loss. The
number of lesions in a patient may vary from 3 to 10, and satellite lesions are
a cardinal feature. Cutaneous nerves within the area of skin lesion may be
thickened, tender, or both 12,13.
Borderline borderline (BB)
Mid borderline (BB) leprosy manifests the clinical morphology of BT as
well as borderline lepromatous (BL) disease. The number of BT-type lesions
tends to equal the number of lepromatous type lesions. Nerves tend to be
affected bilaterally and asymmetrically; may be thickened, tender, or both.
There is variable/partial sensory loss over different types of lesions, but the
loss tends to be coterminous with the clinically apparent skin involvement
12,13.
Histoid leprosy
This is the uncommon presentation of multibacillary leprosy that has distinct
clinical, bacteriologic, and histopathological features. Patients with this type
of disease may present de novo or as a result of secondary drug resistance,
12
with cutaneous and/or subcutaneous nodules and plaques over surrounding
apparently normal skin 12,14.
Pure Neuritic leprosy
This is a type of leprosy that manifests with neural signs and/or symptoms
without any clinically evident skin involvement. It accounts for a significant
proportion of leprosy in Indian subcontinent, nearly 5 – 10% 0f the patients
with leprosy 15. Patients with neuritic  leprosy  have signs and symptoms of
sensory impairment, parasthesia, nerve enlargement, nerve pain, and muscle
weakness, without skin manifestations 14,16.  The  extent  and  distribution  of
nerve involvement is variable and commonly affected nerves are ulnar,
radial, median, lateral popliteal, posterior tibial, facial, and sometimes
trigeminal 17. Mononeuritis or mononeuritis multiplex are the most common
presentations. In patients with mononeuritis single nerve is usually enlarged
and the others may appear thickened. In few cases there is distal symmetric
neuropathy with temperature and pain anesthesia without muscle weakness.
In these cases the tendon reflex may be retained and electromyography
(EMG) may be normal 2,7,8. These case are difficult to diagnose as it will
need sophisticated diagnostic procedures such as bacilloscopy,
electroneuromyography and nerve biopsy. Approach to the neuritic leprosy
will depend on its clinical characteristics, nerve biopsy, and histological
13
appearance of dermatological and neurological lesions. Inflammatory
infiltrate in the nerves may be distinct from the ones in the cutaneous
lesions, being multibacillary in the nerves and paucibacillary in the skin 18–20.
RECENT ADVANCES IN PURE NEURITIC LEPROSY
Leprosy is a disease where Mycobacterium leprae is primarily directed
against specific targets in the peripheral nerves 21-23. Recent research has
clearly demonstrated the gap between clinical and histopathological disease
definition. The majority of patients with pure neuritic leprosy are now
known to have histological evidence of involvement beyond neural tissues.
Simple histological examinations of nasal mucosa and dermatologically
normal skin from hypesthetic regions may be used to reveal the
characteristic changes of leprosy24-27.
Due to the embedding of nerves in the skin, pathophysiological processes
naturally spill over to involve the surrounding tissues even early on in the
disease process. In patients with pure neuritic leprosy established on clinical
examination, typical histological involvement of extra neural tissues occurs
frequently. Samples taken from hypesthetic skin and nasal mucosa, show
specific changes of leprosy in more than 50%.25-27. Abnormalities are
typically seen surrounding the deep dermal nerves and the neurovascular
complexes.25 Changes seen in the nasal mucosa range from macrophage
14
granulomas with acid-fast bacilli, to epithelioid granulomas and nerve
inflammation.25
UPDATES IN THE BIOLOGY OF MYCOBACTERIUM
LEPRAE
The genomic sequencing of M leprae is a major advance, which  assist in
elucidation of the unique biology of the organism28.
M leprae is an acid-fast gram-positive bacillus and an obligate intracellular.
parasite with tropism for macrophages and Schwann cells. The bacilli show
preference for growth in cooler regions of the body. The M leprae genome
includes 1605 genes encoding proteins and 50 genes for stable RNA
molecules.28 More than half of the functional genes in the M tuberculosis
genome are absent and have been replaced by many inactivated genes or
pseudogenes. M leprae seems to have jettisoned genes normally required for
replication ex vivo and assumed a unique ecological niche with a very
limited host range and the need for growth within cells. This gene decay has
removed entire metabolic pathways and regulatory genes, particularly those
involved in catabolism, but the genes essential for the formation of a
mycobacterial cell wall have been retained.29 The leprosy bacillus might
therefore be dependent on host metabolic products, which could explain its
long generation time and inability to grow in culture.28. The unique
predilection of M leprae for Schwann cells is probably determined by the
mycobacterium’s binding to the G domain of the 2 chain of laminin 2, which
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is a component of the basal lamina of Schwann cells.30. This form of laminin
is restricted to peripheral nerves, which explains the specific tropism of M
leprae. The subsequent uptake of M leprae by the Schwann cell depends on
?-dystroglycan, which is the receptor for laminin within the cell membrane,
and other intracellular components.31 Several candidate molecules on the
surface of M leprae bind to this complex, including the specific terminal
trisaccharide of PGL-I and a 21 kDa protein;32,33 however, the specificity of
these interactions has not been fully resolved.34 Once inside the Schwann
cell, the leprosy bacilli replicate slowly over years. At some stage, specific T
cells recognise the presence of mycobacterial antigens within the nerve and
initiate a chronic inflammatory reaction. The Schwann cells can express
HLA class 2 molecules and play an active part in the immunological reaction
by presenting mycobacterial peptides to HLAclass- 2-restricted CD4-
positive T cells.35 Swelling within the inflexible perineurium leads to
ischaemia, further nerve damage, and eventually fibrosis with axonal death.
36.
Host response:
Host genetic factors have a partial effect on both the development of leprosy
and the pattern of disease. Whole-genome screening has identified
susceptibility loci on chromosome 10p13, close to the gene for the mannose
receptor C type 1, a phagocytic receptor on macrophages, and on
chromosome 6 within the MHC.[37] Within this region linkage has been
16
shown to HLA class II genes in Indian patients with leprosy and to the gene
for tumour necrosis factor (TNF) in Brazilian patients38
Fig 1.  Clinical-immuno pathological range of leprosy.
           IL=interleukin; IFN=interferon; ENL=erythema nodosum leprosum.
The varying clinical forms of leprosy are determined by the underlying
immunological response to M leprae 39 (figure 1).
At one pole, patients with tuberculoid leprosy (TT) have a vigorous cellular
immune response to the mycobacterium, which limits the disease to a few
well-defined skin patches or nerve trunks.40 The lesions are infiltrated by
interferon-? and TNF ?-secreting CD4-positive T lymphocytes, which form
well-demarcated granulomas, containing epithelioid and multinucleate giant
17
cells, around dermal nerves.41 Few, if any, acid-fast mycobacteria can be
found in the lesions. Strong cellular immunity is confirmed by T-cell
proliferative and cytokine responses to M leprae antigens in vitro and by
skin-test reactivity to soluble preparations of M leprae and to dead whole M
leprae organisms (Mitsuda reaction). Antibody responses to M leprae
antigens are absent or weak.
At the other pole, lepromatous leprosy (LL) is characterised by the absence
of specific cellular immunity but intact immunity to the related M
tuberculosis. There is therefore uncontrolled proliferation of leprosy bacilli
with many lesions and extensive infiltration of the skin and nerves. The
dermis contains foamy macrophages filled with many bacteria, but few
CD4-positive and CD8- positive T lymphocytes and no organised
granulomas.
There are high titres of antibodies to PGL-I and protein antigens specific for
M leprae, and mycobacterial antigens are readily identified in the urine and
blood.42,43,44  Most patients have the intermediate forms of  borderline
tuberculoid (BT), mid-borderline (BB), and borderline lepromatous (BL)
leprosy. These forms are characterized by a progressive reduction from BT
to BL leprosy in cellular responses, associated with an increasing bacillary
load, more frequent skin and nerve lesions, and higher antibody titres. The
borderline forms are clinically unstable, and patients either show slow
18
change towards the lepromatous pole or experience sudden type I or reversal
reactions.
NERVE DAMAGE
Damage to the nerves occurs in two settings
Peripheral nerve trunks and small dermal nerves.
Peripheral nerves are affected in fibro-osseous tunnels near the surface of
the skin, including the great auricular nerve (neck), ulnar nerve (elbow),
radial-cutaneous nerve (wrist), median nerve (wrist), lateral popliteal nerve
(neck of the fibula), and posterior tibial nerve (medial malleolus). The
posterior tibial nerve is the most commonly affected, followed by the ulnar,
median, lateral popliteal, and facial nerves.45,46 Involvement of these nerves
produces enlargement, with or without tenderness, and standard regional
patterns of sensory and motor loss.
Small dermal sensory and autonomic nerves are affected producing
hypoaesthesia and anhidrosis within borderline tuberculoid and tuberculoid
lesions and glove and stocking sensory loss in lepromatous disease.
Sensation on the hands and feet can be assessed and monitored by use of
Semmes-Weins monofilaments.47
19
NERVE CONDUCTION STUDIES
Problems associated with leprosy neuropathy include loss of sensory and
autonomic nerve functions and muscle strength. In practice, touch/pressure
and muscle strength are the modalities tested in leprosy patients.48,49.
However, the issue of importance lies in the sensitivity, reliability and
reproducibility of any standard assessment method.
The Semmes–Weinstein monofilaments (MF), used for assessing sensory
nerve function are advocated on the grounds that the results are reliable,
since the force required to bend the accurately manufactured monofilaments
is relatively constant and repeatable when used by skilled examiners, and
since they are graded (1–5), they provide a quasi-quantitative estimate of
sensory loss.50,51.
The utility of electrophysiological methods particularly nerve conduction
studies (NCS) in the detection and monitoring of nerve abnormalities in
leprosy and other neuropathies have been well established.52-54 Though not
specific to leprosy neuropathy, NCS is by far more reliable,  reproducible
and has proved a sensitive measure of nerve damage, since it defines small
late components originating from demyelinated, remyelimated or
regenerated fibres. 55-59. The large diameter sensory fibres have lower
thresholds and conduct faster than motor fibres by about 5 to 10% and
fastest sensory conduction velocity is particularly observed amongst mixed
nerves.60 Studies correlating the nerve conduction test findings with the
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clinical tests are few and far between.  Studies by van Brakel, et al. (2005),
as well as Kaplan and Gelber (1985)  have reported a good concordance
between Mono Filament (MF) testing and sensory nerve conduction (SNC)
studies, supporting the validity of monofilaments as standard screening test
of sensory function and the usefulness of clinical testing modalities for
assessing nerve function impairment (NFI). Since NCS is a more sensitive
technique for assessing nerve damage, it is considered as gold standard for
assessing functional nerve impairment.
MECHANISM OF NERVE DAMAGE
The mechanism of nerve damage remains diverse and unclarified.61 It may
be intrafascicular, intraneural, extrafascicular or extraneural lesions.62
Peripheral nerve involvement is usually more and appears earlier in TT than
in LL and also certain nerves are affected more than others in HD.  Croft et
al. found that the most commonly affected nerve by function impairment
was the posterior tibial (sensory) followed by the ulnar nerve. 63,64
Although the route of entry of M. leprae into the body and the method of its
migration to the peripheral nervous system are unknown, it is known that M.
leprae preferentially invade Schwann cells, and that this represents the early
crucial step that leads to sensorimotor loss. 65-68 Although M. leprae has no
locomotory ability, the bacilli can move across endothelium and through
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connective tissue to reach Schwann cells. It is possible that they are
conveyed to the nerve cells by macrophages.69 Another possibility is that
that the bacilli could be transported to nerve cells via intraneural capillaries.
Recent studies have provided an insight into the molecular basis of the
neural tropism of M. leprae, and have identified the Schwann cell receptors
involved in M. leprae infection.30,31
The peripheral nerve comprises myelinated and non-myelinated Schwann-
cell–axon units. In both cases, the Schwann-cell–axon unit is completely
surrounded by the basal lamina, a characteristic feature that distinguishes
Schwann cells from fibroblasts and macrophages. As such, it is reasonable to
assume that the tropism for Schwann cells, and perhaps cellular entry, might
involve components of the Schwann cell basal lamina. The major
components of the basal lamina are laminin-2, collagen IV, heparan sulfate
proteoglycan and entactin/ nidogen70-73. By in vitro analysis of purified
native  components  of  the  Schwann cell  basal  lamina,  it  was  found  that  M.
leprae preferentially bind to laminin-2. Laminin forms major basement
membrane networks and interacts with various extracellular ligands and
cellular receptors.74-76. Such interactions are required for the differentiation
and survival of cells. Laminin has striking effects on Schwann cell behavior
(changes in Schwann cell morphology and proliferation have been observed
when these cells are cultured on laminin substrates), and has also been
implicated in the ensheathment and myelination of axons.
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M. leprae invasion of the Schwann cell represents a crucial early step that
leads to nerve damage in leprosy patients. The deformities resulting from
this nerve damage are largely responsible for the horror and dread of the
disease. Currently, more than onequarter of all reported leprosy patients
worldwide have disabilities, with ~50% being severely disabled.77
Therapeutic intervention has prevented only one-third of infected individuals
from suffering further nerve damage. Many investigators believe that the
best strategy for overcoming neurological damage in leprosy depends on
detecting and preventing the disease at an early stage.
23
RECOMMENDATIONS ON DIAGNOSIS OF PURE
NEURITIC LEPROSY:
Recent epidemiological data reinforces the need for all clinicians to maintain
a high index of suspicion for possible leprosy in patients with unclear
peripheral neuropathy.79 The presence of mononeuritis multiplex, tender and
enlarged nerves should always raise suspicion towards possible underlying
leprosy.80 Sensory nerve biopsy, which is usually performed at the
superficial sensory radial nerve branch at the wrist or the sural nerve is
useful when there are no skin lesions.
In the case of negative or non-specific nerve biopsy findings, the most useful
additional tissue samples are from skin with sensory changes and the nasal
mucosa.81,82.  In  the  case  of  diffuse  sensory  changes,  multiple  small  skin
punch biopsies (3 mm diameter) will increase the likelihood of picking up
specific changes. Needle aspiration of the nerve is a relatively “nerve
sparing” procedure, this may allow examination of motor nerves when
sensory nerves are not involved or cannot be sampled. In the face of clinical
non-specific features with negative histological findings, the physician will
be placed in the difficult position on whether to treat with prednisolone or
wait-and-see. For this situation there are no clear guidelines. In either case,
initial close follow up (monthly) of the peripheral nerve status is mandatory
as new clinical signs may provide diagnostic clarification.
24
NERVE BIOPSY:
Usually a sensory nerve is selected. Most commonly selected nerves are
sural and superficial radial nerves. A small length of the nerve of
approximately 2-4 cms is biopsied and stained with hemotoxylin and eosin
and Fite-Faraco. Both low power and high power microscopy is used to
evaluate and classify the disease.
Nerve fragments comprising of Schwann cells cytologically simulate
epithelioid cell granuloma in low-power screening. It can be differentiated
by morphological details made in high power. The Schwann cells are
spindle-shaped cells of varying sizes with abundant, pale-staining cytoplasm
with pulled out ends, and have oval, centrally or eccentrically, placed
vesicular nuclei with ill-defined nucleoli 83. Epithelioid cell granuloma is
comprised by the collection of epithelioid cells. The epithelioid cells can be
differentiated from Schwann cells by the presence of pale cytoplasm and
vesicular elongated, drawn out, indented or folded nucleus, producing a
shape reminiscent of a footprint. The nuclear chromatin is fine, and nucleoli
are usually inconspicuous. The cytoplasmic margins are indistinct 83.
If the nerve involvement is solitary, the differential diagnosis includes
tumors of the nerve sheath (neurofibromas and schwannomas), sarcoidosis,
and sporotrichosis. In sarcoidosis, the granulomas may be randomly
dispersed from the roots to the distal nerve trunks and branches. In these
cases,  involvement  of  neural  tissue  occurs  after  the  expansion  of  a
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neighboring granuloma, while in leprosy the granulomas occur primarily in
the nerve. Moreover, sarcoidosis usually presents as a multifocal disease
with multiple granulomas in several organs, mainly in the lung tissue. The
diagnosis of sporotrichosis can be suggested by the occurrence of several
abscesses distributed along the lymphatic chains, but with no relation to the
neural tissue. In endemic area of leprosy, pure neuritic leprosy should always
be considered in the investigation of a peripheral neuropathy.  Sarcoidosis
shows open granulomas with the absence of necrosis, acute, and chronic
inflammatory cells and rarely the presence of asteroid bodies or Schaumann
bodies in histiocytes and giant cells. Sporotrichosis shows suppurative
granuloma with surrounding plasma cells and demonstration of fungal
elements.
DIFFERENTIAL DIAGNOSIS
The manifestations of leprosy are protean, and the differential diagnosis is
therefore wide. The consideration of leprosy as a diagnosis and adherence to
the clinical criteria for diagnosing leprosy will facilitate a correct diagnosis.
It can be difficult to diagnose leprosy especially in nonendemic regions or
where the prevalence is very low. Congenital lesions such as nevus
depigmentosus have normal sensation and are present at birth. Vitiligo is
depigmented rather than hypopigmented. Pityriasis alba can be difficult to
distinguish from early disease. Pityriasis versicolor and dermatophyte
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infection may cause diagnostic difficulty. A history of preceding trauma or
inflammation should be sought to rule out postinflammatory
hypopigmentation. The importance of differentiating relatively benign
hypopigmented skin changes from leprosy was emphasized by a recent study
from Mali.84. In some parts of the world, leprosy is a more common cause of
granulomatous lesions than sarcoid, granuloma multiforme, cutaneous
tuberculosis, and granuloma annulare. Cutaneous leishmaniasis does not
usually produce as many nodules as lepromatous leprosy, and the lesions
usually crust and ulcerate after weeks or months. Post kala-azar dermal
leishmaniasis may present with papules and hypopigmented macules and
nodules, which may mimic lepromatous leprosy.
Nerve thickening is a feature of hereditary sensory motor neuropathy type III
and Refsum’s disease. Amyloid, which itself can complicate leprosy, can
cause nerve thickening, and nerve enlargement due to neurofibromatosis
mimicking leprosy has been reported.85
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MATERIALS AND METHODS
STUDY DESIGN
A cross-sectional Study was conducted during the period of January 2010 to
January 2012. Ethical Committee Approval was taken prior to the
commencement of the study.
STUSY SAMPLE:
Seventy patients with clinical signs and symptoms suggestive of pure
neuritic leprosy attending the Neurology clinic and dermatology clinic of
Rajiv Gandhi Government General Hospital, Chennai.
SUBJECTS
INCLUSION CRITERIA
Newly diagnosed patients with clinical suspicion of pure neuritic
hansen’s disease without any leprosy skin lesions.
All patients with sensory loss of  an area or part of the body.
Patients with loss of power  or motor weakness in peripheral nerve
distribution pattern.
Patients with nerve thickening, Nerve tenderness, Nerve swelling or
Abcess.
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Patients with deformities like Wrist drop, Foot drop, Claw hand,
Facial palsy, lagophthalmos without any skin lesions or history of
previous cutaneous Leprosy.
Patients with Trophic ulcer.
Patients who gave written Consent for the Study
EXCLUSION CRITERIA
Patients with skin lesions of leprosy.
Patients with previous history of leprosy skin lesions.
Patients with history of treatment for  Leprosy.
Patients who have known comorbid illnesses such as Diabetes,
connective   tissue disorders, nutritional deficiencies, malignancies etc
are excluded
Patients who refused written Consent.
METHODOLOGY
This study was done over a period of  two years between January 2010 and
2012.
A detailed history with screening for nerve thickening and skin hypo or
hyperpigmentation was done.
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Clinical examination included assessment of power and sensory distribution
areas.
SLIT SKIN SMEAR
Skin Smears from both ear lobes were taken for Acid Fast bacilli
demonstration.
OTHER INVESTIGATIONS
Routine investigations like Complete Blood Count, Random Blood Sugar,
Liver Function Test, Renal Function Test, VDRL, HIV-ELISA, Chest X
Ray, ECG were taken. Appropriate investigations for connective tissue
disorders for suspected cases were done.
ELECTRO DIAGNOSIS
Nerve  conduction  studies  were  done  using  the  RMS  system  with  the
recommended filter settings under room temperature.
MOTOR NERVE CONDUCTION STUDIES
Median and ulnar nerves in both upper limbs
Tibial and peroneal nerves in both lower limbs.
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Distal latencies, amplitudes and conduction velocities were assessed in all
stimulated nerves.
F wave analysis was done in all nerves.
Sensory nerve conduction studies:
Median, ulnar and superficial radial nerves in both upper limbs
Sural nerve in lower limbs
Amplitude and conduction velocity were estimated.
Sympathetic skin response in both upper and lower limbs.
The normal values are taken from standard electrodiagnosis text books and
articles.
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The cut off values for abnormal conduction study is as follows.
CMAPS DL(mS) AMP(mV) CV(mS) Fmin
LAT(Ms)
Median >4 <4 <50 >31
Ulnar >3.5 <4 <50 >31
Tibial >6 <4 <40 >56
Peroneal >6 <2 <40 >56
SNAPS AMP (?V) CV(mS)
Median <10 <50
Ulnar <10 <50
Sural <6 <40
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HISTO PATHOLOGICAL EXAMINATION
After taking a written consent from the patients, left Sural Nerve Biopsy was
done under aseptic precautions under local anaesthesia. Hematoxyllin &
Eosinophil stain and modified Fite Faraco Stains were used to assess the
histopathology and visualization of m.leprae. The histopatological changes
were studied with respect to Nerve tissue damage (Fibre/Axon loss or
Degeneration, Perineural thickening and Fibrosis), Cellular component
(Epitheloid Cells, Giant Cells and Foam Cells), Pattern of inflammation
(Granuloma, Diffuse infiltrates, focal or Sparse infiltrates, Perivascular
infiltrates and Necrosis) and Acid Fast Bacilli demonstration by Fite Faraco.
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RESULTS
CHART 1. BAR CHART  AGE VS SEX
Among the 70 patients, 40(58%) were males and 30(42%) were females.
TABLE   AGE DISTRIBUTION
MEAN 45.98
MEDIAN 46
RANGE 65
MINIMUM 15
MAXIMUM 80
The minimum and maximum age in this study is 15 and 80 yrs and the mean
age is 46 yrs. The range of age is 65 yrs.
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CHART 2: AGE FREQUENCY HISTOGRAM
The age frequency histogram depicts the average age group in this study is
45 to 53 yrs.
35
CHART 3 : CLINICAL PRESENTATION
CLINICAL PRESENTATION
ULNAR 44.7%
MEDIAN 14.7%
ULNAR AND MEDIAN 1.7%
PERONEAL 10.5%
FACIAL 2.5%
POLYNEUROPATHY 25.5%
Ulnar nerve is the most commonly involved nerve (44.7%) followed by
polyneuropathy like pattern 25.5%
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CHART 4: DEFORMITIES (OVERALL)
NO DEFORMITIES 78%
CLAW HAND 11.1%
FOOT DROP 5.1%
TROPHIC ULCER 2.0%
JOINT DEFORMITIES 3.7%
Most  of  the  patients  didn’t  have  any  deformities  at  the  time  of
presentation(78%). Claw hand is the most common deformity observed
(11.1%)
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CHART 5: NERVE THICKENING
NO THICKENING 78.1%
ULNAR UNILATERAL 6.8%
ULNAR BILATERAL 5.4%
ULNAR AND SUPL. RADIAL 2.1%
GREATER AURICULAR 2.4%
ULNAR AND PERONEAL 1.5%
ALL NERVES 3.7%
78.1% of the patients didn’t have nerve thickening. Unilateral ulnar nerve
thickening is the most common nerve thickening observed.
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CHART 6: CATEGORY OF NERVES INVOLVED
MOTOR 54.5%
SENSORY 17.5%
SENSORY MOTOR 28%
Most of the patients presented with motor symptoms such as weakness and
wasting (54.5%) followed by isolated sensory symptoms and mixed motor
and sensory symptoms.
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CHART 7: NERVE BIOPSY
POSITIVE FOR HANSEN’S 20.8%
NEGATIVE FOR HANSEN’S 34.3%
NOT DONE 44.9%
Among the 70 patients, nerve biopsy was not done for 44.9% of the patients.
Biopsy  proved hansen’s positive in 20.8% .
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CHART 8 : DIAGNOSIS
HANSEN’S DISEASE 20.8%
DIABETIC POLYNEUROPATHY 22.6%
DIABETIC MONONEUROPATHY 5.7%
CONNECTIVE TISSUE DISORDERS 10.6%
HMSN 9.5%
HNPP 1.8%
CARPAL TUNNEL SYNDROME 9.2
OTHERS 19.8%
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The most common disease mimicking hansen’s is diabetic polyneuropathy in
previously undiagnosed diabetics, 22.6%. others(19.8%) include
mononeuropathy following injury and in whom biopsy was negative and was
advised follow up.
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CHART 9: ULNAR MOTOR CONDUCTION VELOCITY IN
PATIENTS WITH DEFORMITIES
Ulnar nerve motor conduction velocities are abnormal in 100% of patients
with trophic ulcer and ulnar nerve thickening
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CHART 9: DEFORMITIES IN HANSEN’S DISEASE:
NO DEFORMITIES 60%
CLAW HAND 33.3%
FOOT DROP 6.7%
60% of the patients  didn’t  have any deformities at  the time of presentation
who later tested positive for hansen’s by nerve biopsy
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CHART 10: ABNORMAL SYMPATHETIC SKIN RESPONSE:
SYMPATHETIC SKIN RESPONSE
NORMAL 41.8%
ABNORMAL 58.2%
Of the total number of 70 patients, 58.2%, nearly more than half, had
abnormal sympathetic skin response.
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TABLE 11. ABNORMALITIES IN ULNAR AND MEDIAN
NERVES IN HANSEN’S AND OTHER DISEASES
                   ULNAR
NERVE
                        MEDIAN
NERVE
 SSR
AMP LAT CV SNAP
AMP
AM
P
LAT CV SNAP
AMP
NORMAL(%) 31.5 56 48.9 34.3 50.7 65.2 64.8 50.1 41.8
ABNORMAL(%) 68.5 44 51.1 63.7 49.3 34.8 35.2 49.9 58.2
NORMAL IN
HANSEN’S (%)
43.8 52 56 31.3 87.5 93.8 98.0 93 31.3
ABNORMAL IN
HANSEN’S (%) 56.2 48 44 68.8 12.5 6.2 2.0 7 68.8
Ulnar nerve showed significant abnormalities in biopsy proven Hansen’s
disease. 70% abnormalities are seen in SNAPs and 56.2% in motor
amplitudes.
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CHART 12: CLINICAL PRESENTATION IN HANSEN’S
DISEASE
ULNAR                68.8%
PERONEAL                18.8%
FACIAL                6.3%
POLYNEUROPATHY                6.1%
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CHART 13: SYMPATHETIC SKIN RESPONSE IN HANSEN’S
DISEASE
SSR NO OF PATIENTS WITH BIOPSY POSITIVE
NORMAL 5 (45%)
ABNORMAL 11 (55%)
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CHART 14: SURAL NERVE SNAPS IN HANSEN’S DISEASE
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CHART 15: SPLIT SKIN SMEAR AND SYMPATHETIC
SKIN RESPONSE CORRELATION
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CHART 16: CLINICAL TYPES IN HANSEN’S DISEASE
MOTOR 62.5%(10)
SENSORY 31.3%(5)
SENSORYMOTOR 6.2%(1)
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DISCUSSION
Of the 70 patients who were clinically suspected to have leprosy, 16 were
later proven by nerve biopsy to have hansen’s disease.
Kumar  et  al[78]  has  reported  a  male:  female  sex  ratio  of  2.6:1  with  male
predominance. In our study, 81%(13) were males and 19%(3) were females.
Though  multiple symptoms have been observed at the time of presentation,
sensory deficit was most common, followed by motor symptoms and
Trophic changes, according to  Kumar et al. However in this study, motor
symptoms were the predominant presenting symptom followed by sensory
and trophic ulcers. Probable reason may be that motor symptoms are noted
earlier by the patients and they are disabling which makes the patients to
sought medical attention in case of pure neuritic hansen’s disease.
Almost all the patients diagnosed with hansen’s disease showed abnormal
nerve conduction studies.  Patients with suspected clinical features of
hansen’s were later subjected to nerve biopsy. Nerve conduction studies
were also abnormal in many other diseases such as rheumatoid arthritis,
diabetes and carpal tunnel syndromes. In case of diabetes with mono
neuropathy, NCS was abnormal in non-involved nerves also.
In a study of “Clinical, electrophysiological, and immunopathological study
of peripheral nerves in Hansen's disease” by Ramadan et al claw hand was
the most common disability among their patients which indicates that ulnar
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nerve is the most affected nerve in leprosy patients. Similarly in this study
also claw hand was the most common deformity and ulnar nerve is most
commonly involved. Antia et al has shown that the motor nerve conduction
studies of ulnar nerves are more frequently abnormal than that of median
nerve. This study also showed the same pattern with ulnar nerve distal
latencies, amplitudes and F waves being more abnormal than the other
nerves examined.
Ramadan et al in his study has found that ulnar nerve sensory nerve action
potentials(SNAP) were more affected than that of the compound muscle
action potentials (CMAPs). In this study both sensory and motor potentials
were equally affected in patients with clinical involvement of ulnar nerve.
The  reason  for  this  could  be  that  most  of  the  patients  in  his  study  by
Ramadan et al had sensory disturbances in the ulnar nerve distribution
whereas in this study the most common presenting symptom was motor and
hence both sensory and motor component of ulnar nerve were equally
affected.
Mshana et al. mentioned that some nerves that appeared to be clinically
normal have been shown to have pathological changes. In this study,
patients who presented with symptoms of mononeuritis multiplex didn’t
show any evidence for involvement of other nerves electrophysiologically.
However, those patients who didn’t have sural nerve involvement clinically
and electrophysiologically, later underwent sural nerve biopsies which
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revealed findings conforming with hansen’s disease. These indicate that the
earlier pathologic changes that can occur in non-involved nerves in hansen’s
are not detected in routine nerve conduction studies.
Leprosy is a disease predominantly early involvement of small fibres. These
routine nerve conduction studies may not detect the abnormalities of the
small fibres. However, sympathetic skin response is a measure of the small
fibre intactness. Sympathetic skin response can be abnormal earlier in many
other neuropathies caused by systemic illnesses namely diabetes, alcohol etc.
In this study sympathetic skin response was abnormal in all of the patients
with biopsy positive for Hansens disease. But sympathetic skin response was
also abnormal in some other diseases which comes under the differential
diagnosis for Hansen’s disease such as diabetes, connective tissue disorders,
HIV neuropathy etc. Hence sympathetic skin response, even if abnormal,
cannot detect or suspect hansen’s disease with high specificity.
Split  skin  smear  studies  didn’t  show  any  abnormality  in  any  of  the  cases.
This could be because of the pauci bacillary nature of the disease and low
sensitivity index of the test.
With respect to the histo pathological results most of the patients diagnosed
as Hansen’s disease showed chronic granulomatous infiltrate with foamy
macrophages with minimal or no fibrosis. This was in contrast to the study
by Van Brakel and Khawas, in which fibrosis was the predominant finding
in nerve biopsy with little or no inflammation. This could be due to the
54
duration of the disease. In this study most of the patient presented within 1
year of the onset of illness. In his study most of the patients had disease for
more than two to four years thereby chronic inflammation which might have
progressed to fibrosis.
Though the incidence of leprosy is decreasing, this study has found that
incidence of pure neuritic hansen’s is still may be the same with detection of
16  new cases in 2 years. However, this institute being a tertiary care centre
catering the needs of most of south India, the incidence may look
abnormally high. It may need a broad cross sectional study including the
primary and secondary care centres to assess the true incidence of pure
neuritic hansen’s. The most common cause for this is the delay in detection
and treatment. The delay is primarily because of the absent skin
manifestations. Pure neuritic hansen’s needs a high index of suspicion for an
earlier diagnosis.
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CONCLUSION
? Nerve conduction studies including sympathetic skin response are
abnormal in all patients with pure neuritic  hansen’s disease.
? Abnormalities in motor or sensory nerve conduction studies or
sympathetic skin responses alone cannot predict the possibility of
Hansen’s disease.
? Nerve biopsy clinches the diagnosis.
? There is a high degree of electrophysiological and nerve biopsy
correlation for Pure Neuritic Hansen’s disease, though it is not
specific.
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DIAGNOSTIC SIGNIFICANCE OF NERVE CONDUCTION
STUDIES IN EARLY DETECTION OF PURE NEURITIC
HANSEN’S DISEASE
Name of the Participant :
Name of the Institution :
Name and address of the sponsor/
agency (ies) (if any) :
Documentation of the informed consent
I _____________________________ have read the information in this
form (or it has been read to me). I was free to ask any questions and they
have been answered. I am over 18 years of age and, exercising my free
power of choice, hereby give my consent to be included as a participant.
1. I have read and understood this consent form and the information
provided to me.
2. I have had the consent document explained to me.
3. I have been explained about the nature of the study.
4. I have been explained about my rights and responsibilities by the
investigator.
5. I have been informed the investigator of all the treatments I am taking
or have taken in the past ________ months including any native
(alternative) treatment.
6. I have been advised about the risks associated with my participation in
this study.
7. I agree to cooperate with the investigator and I will inform him/her
immediately if I suffer unusual symptoms.
8. I have not participated in any research study within the past
_________month(s).
9. I have not donated blood within the past _______ months—Add if the
study involves extensive blood sampling.
10.I am aware of the fact that I can opt out of the study at any time
without having to give any reason and this will not affect my future
treatment in this hospital.
11.I am also aware that the investigator may terminate my participation in
the study at any time, for any reason, without my consent.
12.I hereby give permission to the investigators to release the information
obtained from me as result of participation in this study to the
sponsors, regulatory authorities, Govt. agencies, and IEC. I understand
that they are publicly presented.
13.I have understand that my identity will be kept confidential if my data
are publicly presented
14.I have had my questions answered to my satisfaction.
15.I have decided  to  be  in  the  research  study.  I  am  aware  that  if  I  have
any question during this study, I should contact the investigator. By
signing this consent form I attest that the information given in this
document has been clearly explained to me and understood by me, I
will be given a copy of this consent document.
For adult participants:
Name and signature / thumb impression of the participant (or legal
representative if participant incompetent)
Name : Signature : Date :
Name and Signature of impartial witness (required for illiterate patients):
Name : Signature : Date :
Address and contact number of the impartial witness:
Name and Signature of the investigator or his representative obtaining
consent:
Name : Signature : Date :
PROFORMA
A STUDY OF DIAGNOSTIC VALUE OF NERVE
CONDUCTION STUDIES IN PURE NEURITIC HANSEN’S
NEUROPATHY
Name : MIN No. :
Age : IP No :
Sex : Duration of  DM :
Address :
Contact Number :
Occupation :
HISTORY
1. Motor Symptoms : Thinning, flailness, weakness (D,P), gait
disturbance
2. Sensory Symptoms : Burning / tingling / cramps/ pins and needles,
pricking / aching / numbness /  Loss  of touch, pain and temperature
sensations.
3. SKIN CHANGES: Hypo or hyperpigmentation
4. Previous H/O hansen’s treatment
H/o PTB, ATT
H/o STD
H/o Hypothyroidism, polyarthritis
Personal History
Contact with Hansen’s patient
Smoking
Drug Abuse
Diet
Family History
Hypertension
Diabetes Mellitus
Chronic Kidney Disease
Neuropathy
Connective tissue disorders
Treatment History
EXAMINATION
Signs of Hyperlipidemia
BP
HR
Pallor
Pedal Edema
Peripheral pulses
RS
CVS
P/A
CNS :
Motor system -
Bulk
Tone
Power
DTR
Gait
Sensory system -
Pin Prick
Touch
Temperature
Timed Vibration
Position sense
Romberg's Test
Autonomic nervous system -
Sweating abnormalities
Trophic  changes
HRV
SSR
Investigations
CBC
Urine RE
FBS
PPBS
HbA1c
Serum Lipids
Urea, Creatinine
LFT
Connective tissue disorders screening
NERVE CONDUCTION STUDY
Motor : Distal Latency
Amplitude
Conduction Velocity
Sensory : Latency
Amplitude
Conduction Velocity
F Wave Studies:
F mean
H - Reflex
INSTITUTE OF NEUROLOGY
MADRAS MEDICAL COLLEGE, CHENNAI - 3
NERVE CONDUCTION STUDY
Name : Age / Sex : Date:
MIN No. : Unit :
MOTOR NERVE CONDUCTION STUDY
Nerve
Distal
Latency
(ms)
Amplitude
(mv) CV (m/s)
F-Wave
Latency (ms)
R. Median
L. Median
R. Ulnar
L. Ulnar
R. Tibial
L. Tibial
R. Peroneal
L. Peroneal
SENSORY NERVE CONDUCTION STUDY
Nerve Latency (ms) Amplitude(µv) CV (m/s)
R.Median
L.Median
R. Ulnar
L. Ulnar
R. Sural
L. Sural
Sympathetic skin response:
Slit skin smear:
Nerve biopsy:
age sex
nerve
thickening
type clinical side deformity duration MDL UDL TDL PDL MDA UDA TDA PDA MCV UCV TCV PCV MF UF TF
31 2 2 1 1 1 2 6 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
25 1 3 2 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
46 1 1 2 3 2 3 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
18 1 6 1 4 2 1 5 1 1 1 2 1 1 1 2 1 1 1 1 1 1 1
51 1 1 1 2 3 1 4 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
18 1 5 1 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
26 1 1 2 1 2 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
56 2 1 3 2 2 4 5 2 1 1 1 2 1 1 1 1 1 1 1 2 1 1
15 1 1 1 4 3 1 24 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
45 2 1 1 2 3 1 6 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
37 1 1 1 1 1 1 7 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
28 2 1 1 2 3 1 8 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
34 1 1 2 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
57 2 1 3 1 1 1 9 1 1 1 1 2 2 2 2 2 1 1 1 1 1 1
30 2 1 1 2 3 1 5 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
45 1 2 2 1 2 1 6 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
65 2 1 3 1 3 1 12 1 1 1 1 2 2 2 2 1 1 1 1 1 1 1
32 1 3 1 1 3 2 12 1 2 1 1 2 2 1 2 1 2 1 1 1 2 1
47 1 1 1 1 3 1 11 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
24 1 7 3 6 3 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
22 1 7 3 6 3 1 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
57 2 7 3 6 3 1 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
18 2 1 2 1 1 1 7 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1
39 1 1 2 1 2 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1
45 1 1 1 2 3 1 8 2 2 2 2 2 2 1 2 1 1 1 2 1 1 1
22 1 2 1 1 1 2 2 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
57 2 1 3 4 3 1 10 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
59 1 1 1 1 1 1 12 1 2 1 1 1 2 2 1 1 2 1 1 1 2 1
29 2 1 1 2 3 1 7 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
45 1 1 3 6 3 1 12 2 1 1 2 2 1 1 2 1 1 1 1 2 1 1
15 1 3 1 1 3 5 24 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
38 2 1 1 2 1 1 9 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
49 1 2 1 1 1 2 8 1 1 1 1 1 2 1 1 1 2 1 1 1 2 1
58 2 1 1 4 1 1 12 1 1 1 2 1 1 1 1 1 1 1 2 1 1 1
PF MSNAP USNAP SURSNAP SRSNAP SSR SSS BIOPSY DIAGNOSIS
1 1 2 1 1 2 1 1 1
1 1 2 1 1 2 1 1 1
1 1 1 1 1 1 1 3 8
1 1 1 1 1 1 1 1 1
1 1 2 1 1 2 2 3 8
1 1 1 1 1 1 1 3 8
1 1 2 2 2 1 1 1 1
1 2 1 1 1 1 3 3 8
2 2 2 2 2 2 3 2 2
1 2 1 1 1 1 3 3 6
1 1 1 1 1 1 1 2 8
1 2 1 1 1 1 3 3 6
1 1 2 1 1 2 3 3 8
1 2 2 2 1 2 3 3 4
1 2 1 1 1 1 3 3 6
1 1 2 2 2 1 1 1 1
1 2 2 2 1 2 3 3 4
2 1 2 2 1 2 1 1 1
2 2 2 2 2 2 3 3 4
2 2 2 2 2 2 3 3 2
2 2 2 2 2 2 3 3 2
2 2 2 2 2 2 3 3 2
1 1 2 2 1 2 1 1 1
1 1 2 1 1 2 1 1 1
1 2 2 2 1 2 3 3 4
1 1 2 1 1 2 1 1 1
2 2 2 2 2 2 3 3 4
1 1 1 1 1 1 1 2 4
1 2 1 1 1 2 3 3 6
2 2 1 1 2 2 1 1 1
1 1 2 1 1 2 1 2 7
1 2 1 1 1 1 3 3 6
1 1 2 1 1 2 1 1 1
2 1 1 1 2 1 3 3 8
25 1 6 1 6 3 1 36 2 2 1 2 2 2 1 2 1 1 1 2 2 2 1
36 2 1 1 1 1 1 8 1 2 1 1 1 2 1 1 1 2 1 1 1 1 1
48 1 5 1 5 1 2 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
50 1 1 1 1 1 3 1 2 1 1 1 2 1 1 1 2 1 1 1 1 1
36 1 1 1 4 1 3 6 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1
26 2 2 1 1 1 1 8 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
16 1 1 3 6 3 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
57 2 1 3 6 3 1 12 1 1 1 1 2 2 2 2 1 1 1 1 1 1 1
72 1 1 1 4 1 1 5 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1
29 1 1 2 1 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
67 2 1 3 6 3 1 18 1 1 1 1 2 2 2 2 1 1 1 1 1 1 1
49 2 1 1 1 3 5 24 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
23 1 1 2 1 3 1 3 1 1 1 1 1 2 1 2 1 1 2 2 1 2 1
37 2 1 3 6 3 1 8 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2
80 1 3 1 1 3 2 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
25 1 4 2 1 1 1 12 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
22 1 1 1 5 3 1 1 1 2 2 1 1 2 2 1 2 2 2 2 2 2 2
37 2 1 1 1 3 5 12 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
53 2 1 3 6 3 1 15 1 1 1 1 2 2 2 2 1 1 1 1 1 1 1
58 1 1 3 6 3 1 6 1 1 1 1 1 2 2 2 1 2 2 2 1 2 2
68 1 1 3 6 3 1 35 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2
18 2 2 1 1 1 1 6 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
33 1 4 1 1 3 1 3 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
47 1 1 1 2 3 1 6 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
41 1 1 2 1 3 1 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
40 2 1 2 1 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
43 1 1 1 1 1 2 7 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1
46 2 1 2 1 3 1 12 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1
38 2 1 3 6 3 1 5 1 1 1 1 2 2 2 2 1 1 1 1 1 1 1
35 1 1 1 6 3 3 36 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
65 2 1 1 6 3 1 12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
47 1 1 1 6 3 1 12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
35 2 1 2 4 3 1 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
40 1 1 1 2 3 1 8 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1
15 1 1 2 1 1 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
57 1 1 1 1 2 1 6 1 1 1 1 1 2 1 1 1 2 1 1 1 2 1
2 1 1 1 1 1 3 2 3
1 1 2 1 1 1 3 2 7
1 1 1 1 1 1 1 1 1
1 1 2 1 1 2 1 1 1
2 1 1 2 1 1 1 1 1
1 1 2 1 1 2 1 1 1
1 1 1 1 1 1 2 8
1 2 2 2 2 2 3 3 4
2 1 1 2 2 2 1 1 1
1 1 1 1 1 1 1 2 8
1 2 2 2 2 2 1 2 4
2 2 2 2 2 2 1 2 7
2 1 1 1 1 1 1 2 5
2 2 2 2 2 2 1 3 5
2 2 2 2 2 1 2 8
1 1 2 1 1 1 1 2 3
1 2 1 1 1 3 3 8
1 1 2 1 1 1 3 3 7
1 2 2 2 2 2 3 3 4
2 1 2 2 2 1 1 2 4
2 2 2 2 2 2 3 3 4
1 1 2 1 1 1 3 3 8
1 1 2 1 1 1 1 3 8
1 2 1 1 1 1 3 3 6
1 1 1 1 1 1 1 2 8
1 1 1 1 1 1 3 2 7
1 1 2 1 1 2 1 2 5
1 2 2 1 1 2 1 2 7
1 2 2 2 2 2 3 3 7
2 2 2 2 2 2 3 2 2
2 2 2 2 2 2 3 2 2
2 2 2 2 2 2 3 2 2
1 1 1 2 1 1 3 2 7
1 2 1 1 1 1 3 3 6
1 1 2 1 1 2 1 2 8
1 1 1 1 1 1 2 5
MASTER CHART REFERENCE
SEX 1. MALE
2. FEMALE
NERVE THICKENING 1. NO THICKENING
2. ULNAR UNILATERAL
3. ULNAR BILATERAL
4. ULNAR AND SUPL. RADIAL
5. GREATER AURICULAR
6. PERONEAL
7. ALL NERVES
TYPE 1. MOTOR
2. SENSORY
3. SENSORYMOTOR
CLINICAL 1. ULNAR
2. MEDIAN
3. ULNAR AND MEDIAN
4. PERONEAL
5. FACIAL
6. POLYNEUROPATHY
SIDE 1. LEFT
2. RIGHT
3. BILATERAL
DEFORMITY 1. NO DEFORMITY
2. CLAW HAND
3. FOOT DROP
4. TROPHIC ULCER
5. JOINT DEFORMITIES
MEDIAN DISTAL LATENCY (MDL)
ULNAR DISTAL LATENCY    (UDL)
TIBIAL DISTAL LATENCY     (TDL)
PERONEAL DISTAL LAT (PDL)
MEDIAN DISTAL AMPLITUDE (MDA)
ULNAR DISTAL AMPLITUDE   (UDA)
TIBIAL DISTAL AMPLITUDE (TDA)
PERONEAL DISTAL AMPLITUDE (PDA)
MCV, UCV, TCV, PCV – MEDIAN, ULNAR, TIBIAL AND PERONEAL
CONDUCTION VELOCITIES
MF, UF,TF.PF – MEDIAN, ULNAR, TIBIAL AND PERONEAL F WAVE
LATENCIES
MSSNAP, USSNAP,  SURSNAP, SRSNAP – MEDIAN, ULNAR, SURAL
AND SUPERFICIAL RADIAL SENSORY NERVE ACTION
POTENTIALS
1. NORMAL
2. ABNORMAL
SSS – SPLIT SKIN SMEAR 1. NORMAL
2. ABNORMAL
SSR – SYMPATHETIC SKIN RESPONSE 1. NORMAL
2.ABNORMAL
NERVE BIOPSY 1. POSITIVE FOR HANSEN’S
2.NEGATIVE FOR HANSEN’S
3.NOT DONE
DIAGNOSIS 1. HANSEN’S DISEASE
2. HMSN
3. HNPP
4. DIABETIC POLYNEUROPATHY
5. DIABETIC MONONEUROPATHY
6. CARPAL TUNNEL SYNDROME
7. CONNECTIVE TISSUE DISORDERS
8. OTHERS( INJURY, FOLLOW UP)
